Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multi-Center, Double-Blind, Randomized, Placebo-Controlled Trial to Assess Efficacy and Safety of Omecamtiv Mecarbil in Patients With Symptomatic Heart Failure With Severely Reduced Ejection Fraction (COMET-HF)

NCT06736574 is registered in ClinicalTrials.gov with Cytokinetics as lead sponsor.

NCT NCT06736574
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06736574 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multi-Center, Double-Blind, Randomized, Placebo-Controlled Trial to Assess Efficacy and Safety of Omecamtiv Mecarbil in Patients With Symptomatic Heart Failure With Severely Reduced Ejection Fraction (COMET-HF)
Lead sponsor
Cytokinetics
Phase
Phase 3
Overall status
Recruiting
Start date
December 19, 2024
Completion date
December 31, 2027
Enrollment
1,800 (estimated)
Sites
209

Conditions

As the registry lists them; a condition with its own page is linked.

heart failure, heart failure with reduced ejection fraction